Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Boehringer Ingelheim
McKesson
Express Scripts
Johnson and Johnson
Citi

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 9,023,350

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,023,350
Title:Synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animals
Abstract: A synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovasculization (angiogenesis) and in other organs, in a human being or animal, characterized in comprising, in a pharmaceutically acceptable vehicle or carrier: 60 to 90 weight % Suramine, or the equivalent of one of the pharmaceutically acceptable salts thereof; and 40 to 10 weight % Bevacizumab; wherein said percentages are relative to the addition of weight of both active principals. Said synergistic pharmaceutical composition is under the form of an injectable composition by intravenous, intravitrea or subconjuntival means or under the form for topical administration.
Inventor(s): Gallo Barraco; Juan Eduardo Maria (Buenos Aires, AR)
Assignee: Association Civil de Estudios Superiores (Ciudad de Buenos Aires, AR)
Application Number:12/735,659
Patent Claims:see list of patent claims

Details for Patent 9,023,350

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ➤ Sign Up Association Civil de Estudios Superiores (Ciudad de Buenos Aires, AR) 2027-08-07 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ➤ Sign Up Association Civil de Estudios Superiores (Ciudad de Buenos Aires, AR) 2027-08-07 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Harvard Business School
Fish and Richardson
Cantor Fitzgerald
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.